• Explore /
  • Poster
  • / Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.

Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.

Abstract Poster

Authors

null

Georg Martin Haag

Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany

Georg Martin Haag , Niels Halama , Christoph Springfeld , Barbara Grün , Leonidas Apostolidis , Stefanie Zschaebitz , Mareike Dietrich , Anne-Katrin Berger , Tim Frederik Weber , Inka Zoernig , Lisa Waberer , Daniel Wilhelm Mueller , Salah-Eddin Al-Batran , Dirk Jaeger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03274804

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3010)

DOI

10.1200/JCO.2020.38.15_suppl.3010

Abstract #

3010

Poster Bd #

74

Abstract Disclosures

Similar Posters

First Author: Robert William Lentz

First Author: Atsushi Ishiguro

First Author: John C. Krauss

First Author: Guillem Argiles